Connect with us

Futures Slide As Snap Forecast Steamrolls Rebound Optimism

Futures Slide As Snap Forecast Steamrolls Rebound Optimism

It’s not every day that a relatively small social media company (whose market cap…

Published

on

Futures Slide As Snap Forecast Steamrolls Rebound Optimism

It's not every day that a relatively small social media company (whose market cap is now less than Twitter) slashing guidance can send shockwaves across global markets and wipe out over a trillion in market cap, yet SNAP's shocking crash after it cut its own guidance released one month ago which hammered risk assets around the globe, and here we are. Add to this the delayed realization that Biden was just spouting his usual senile nonsense yesterday when he said Chinese trade tariffs would be discussed and, well, wave goodbye to the latest dead cat bounce as futures unwind much of Monday's rally.

US futures declined as technology shares were set to come under pressure after Snap warned it would miss second-quarter profit and revenue forecasts amid deteriorating macroeconomic trends. Nasdaq 100 futures slid 1.5% at 7:30 a.m. ET and S&P 500 futures retreated 1.0% just as the benchmark was starting to pull back from the brink of a bear market amid fears the Federal Reserve’s tightening could hurt growth. Meanwhile in other markets, Chinese tech stocks fell by more than 4%, while Europe’s Stoxx 600 Index dropped 1%, led by losses in shares of utilities and retail companies. The dollar was little changed, while Treasuries advanced.

Snapchat plunged more 31% in premarket trading, while Facebook Meta and other companies that rely on digital advertising also tumbled amid fears that the sudden collapse in ad spending is systemic. Technology shares have been hammered this year amid rising interest rates and soaring inflation, with the Nasdaq 100 trading near November 2020 lows and at the cheapest valuations since the early days of the pandemic. Social media stocks are on course to erase more than $100 billion in market value Tuesday after Snap’s warning: Meta Platforms (FB US) declined 6.3%, Twitter (TWTR US) -4.1%, Alphabet (GOOGL US) -3.8% and Pinterest (PINS US) -12%.

“It highlights how fleeting swings in sentiment are now and also that investors are running at the first sign of trouble,” Jeffrey Haley, a senior market analyst at Oanda Asia Pacific, wrote in a note. “The market continues to turn itself inside out and back to front as it tries to decide if it has priced all of the impending rate hikes, soft landing or recession, inflation or stagflation, China, Ukraine, US summer driving season, supply chains, the list goes on.”

Among other notable moves in US premarket trading, Zoom Video’s shares rallied as much as 6.3% after better-than-expected guidance. Deutsche Bank said the video-software maker’s continued post-pandemic growth in its Enterprise business is encouraging, though analysts remain cautious on the company’s comments around free cash flow. Tesla shares fell 2.6% in premarket trading on Tuesday, amid news that it may take the electric-vehicle maker at least until later this week to resume full production at its China factory. Also, Daiwa analyst Jairam Nathan lowered his price target on TSLA to $800 from $1150, the latest in a string of target cuts by Wall Street analysts. Nathan cited the lockdowns in Shanghai and supply chain concerns impacting ramp-up of Austin and Berlin plants, and lowered the EPS estimates for 2022 and 2023. Elsewhere, Frontline shares rallied 3.1% after the crude oil shipping company reported net income for the first quarter that beat the average analyst estimate. Here are some other notable premarket movers:

  • Social media and other digital advertisers fell in US premarket trading after Snap cut its forecasts.
  • Albemarle (ALB US) shares may be in focus as analysts raise their price targets on the specialty chemicals maker amid a boost from higher lithium prices.
  • BitNile (NILE US) swings between gains and losses in US premarket trading, after the crypto miner reported 1Q results amid a broader slump across high-growth stocks.
  • Nautilus (NLS US) got a new Street-low price target after exercise equipment maker’s “lackluster” guidance, with the company’s shares slumping as much as 24% in US extended trading on Monday.
  • INmune Bio (INMB US) shares dropped 23% in postmarket trading on Monday after the FDA placed the company’s investigational new drug application to start a Phase 2 trial of XPro in patients with Alzheimer’s disease on clinical hold.
  • Abercrombie & Fitch (ANF IS)  falls as much as 21% premarket after the clothing retailer reported an unexpected loss for its first quarter

Equities have been volatile as investors assess the outlook for monetary policy, inflation and the impact of China’s strict Covid policies on the global economy. Minutes on Wednesday of the most recent Federal Reserve rate-setting meeting will give markets insight into the US central bank’s tightening path.

“With the era of cheap money hurtling to an end the focus will be on a speech from Jerome Powell, the chair of the Federal Reserve later, with investors keen to glean any new titbit of information about just how far and fast the US central bank will go in raising rates and offloading its mass bond holdings,” Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown, wrote in a note.

In Europe, the Stoxx 50 slumped 1.4%. FTSE 100 outperformed, dropping 0.6%, while CAC 40 lags. Utilities, retailers and consumer products are the worst performing sectors. Utilities were the biggest decliners in Europe, as Drax Group Plc, Centrica Plc and SSE Plc all sank on Tuesday following a report about UK plans for a possible windfall tax. Air France-KLM fell after plans to sell about 2.26 billion euros ($2.4 billion) of new shares to shore up its balance sheet. Oil and gas stocks underperformed the European equity benchmark in morning trading as crude declines amid investors’ concerns about Chinese demand, while mining shares also fall alongside metal prices.  Here are some of the biggest European movers:

  • Big Yellow shares gain as much as 4% after what Citi described as a “strong set” of results, supported by structural tailwinds.
  • SSP rises as much as 13% after the U.K. catering and concession-services company reported 1H results that Citi says were above expectations.
  • Adevinta climbs as much as 7.8% after reporting 1Q results that were broadly as expected, with revenue slightly below expectations and Ebitda ahead, according to Citi.
  • Frontline gains as much as 6.4% in Oslo after the crude oil shipping company reported 1Q net income that beat the average analyst estimate.
  • Moonpig gains as much as 8.2%, extending a rise of 11% on Monday when the company announced the acquisition of Smartbox Group UK
  • U.K. utility firms sink after the Financial Times reported that Chancellor of the Exchequer Rishi Sunak has ordered officials to prepare plans for a possible windfall tax on power generators as well as oil and gas firms. SSE declines as much as 11%, Drax Group -19% and Centrica -12%
  • European technology and advertising stocks slump with Nasdaq futures after Snap cut its revenue and profit forecasts below the low end of its previous guidance. Just Eat falls as much as 4.8%, Deliveroo -4.9%, Delivery Hero -4.4%, STMicro -3%, Infineon -2.8%, AMS -3%
  • Prosus drops as much as 6.7% in Amsterdam and Naspers declines as much as 6.1% in Johannesburg as Barclays cuts ratings on both stocks after downgrading Tencent in the prior session.

The latest flash PMI data showed that Europe’s two largest economies kept growing in May as they benefited from a sustained rebound in services that offset fallout from Russia’s invasion of Ukraine. Meanwhile, the pound fell after a report showed the UK economy faces an increasing risk of falling into a recession as firms and households buckle under the fastest inflation rate in four decades. At the same time, the euro climbed above $1.07 for the first time in four weeks as ECB President Christine Lagarde said the currency bloc has reached a “turning point” in monetary policy and rejected the idea that the region is heading for a recession, but said the ECB won’t be rushed into withdrawing monetary stimulus.

Earlier in the session, Asian stocks dipped as traders remained cautious on global growth concerns while assessing the impact of China’s fresh fiscal stimulus.  The MSCI Asia Pacific Index fell as much as 1.2%, with tech names the biggest drags. Lower revenue and profit forecasts from Snap Inc. weighed on the broader sector. Chinese stocks led declines in the region as the government’s new support package including more than 140 billion yuan ($21 billion) in additional tax relief failed to impress investors. Covid-19 lockdowns remain a key overhang, while market participants are looking to major China tech earnings this week, including Alibaba and Baidu, for direction. Hong Kong equities also dropped after the city’s outgoing leader said border controls will remain in place for now.  Hong Kong’s Hang Seng Tech Index tumbles as much as 4.2% in afternoon trading on Tuesday, on track for a second day of declines. 

“Markets have caught a glimpse of the impact of regulatory risks and Covid-19 lockdowns from Tencent’s recent lackluster earnings,” and a potential mirroring of the weakness by big tech earnings ahead “may be driving some caution,” Jun Rong Yeap, a market strategist at IG Asia Pte., wrote in a note

Japanese equities dropped as investors mulled China’s new stimulus measures and amid growing concerns over global economic health.  The Topix Index fell 0.9% to close at 1,878.26 on Tuesday, while the Nikkei declined 0.9% to 26,748.14. Recruit Holdings Co. contributed the most to the Topix’s decline, as the staffing-services firm tumbled 6.6%. Among the 2,171 shares in the index, 1,846 fell, 249 rose and 76 were unchanged. “The markets will continue to be in an unstable situation for a while as the US is still in the process of raising its interest rates and we are entering a phase where the effects of interest rate tightening on the economy will start to be felt in the real economy,” said Hiroshi Matsumoto, senior client portfolio manager at Pictet Asset Management.

Indian stocks also declined, dragged by a selloff in information technology firms, as investors remained cautious over global economic growth.  The S&P BSE Sensex fell 0.4% to 54,052.61 in Mumbai while the NSE Nifty 50 Index eased 0.6%. The gauges have now dropped for four of five sessions and eased 5.3% and 5.7% this month, respectively. All but two of the 19 sector sub-indexes compiled by BSE Ltd. declined on Tuesday, led by information technology stocks. Foreign funds have been net sellers of Indian stocks since end of September and have taken out $21.3 billion this year through May 20. The benchmark Sensex is now 12.5% off its peak in Oct. Corporate earnings for the March quarter have been mixed as 26 out of 41 Nifty companies have reported profit above or in line with consensus expectations. “There is a lot of skepticism among investors over interest rate hikes in the near term and its impact on growth going ahead,” according to Kotak Securities analyst Shrikant Chouhan.

In FX, the dollar dipped while the euro jumped to a one-month high versus the US dollar after the European Central Bank reiterated its plans to end negative rates quickly, bolstering market expectations that rates will rise as early as July. It pared some gains after ECB Governing Council’s Francois Villeroy de Galhau argued against a 50 bps increase. “The single currency is dancing to the tune of ECB policymakers this week as the Governing Council attempts to talk up the euro to insure against imported inflation,” said Simon Harvey, forex analyst at Monex Europe. “The euro’s rally highlights how dip buyers are happy to buy into the ECB’s messaging in the near-term.”

Elsewhere, the pound slid and gilts rallied after a weak UK PMI reading ramped up speculation that the country is heading toward recession. The Australian and New Zealand dollars led declines among commodity currencies after Snapchat owner Snap Inc. slashed its revenue forecast, spurring doubts about the strength of the US economy. Japan’s yen snapped a two-day drop as Treasury yields resumed their decline. Japanese government bond yields eased across maturities, following their US peers.

In rates, Treasuries were richer by up to 4bp across belly of the curve as S&P futures gapped lower from the reopen and extended losses over Asia, early European session. Treasury 10-year yields around 2.815%, richer by 3.5bp vs. Monday close US session focus to include Fed Chair Powell remarks and 2-year note auction. Gilts outperformed following soft UK data. Gilts outperform by additional 1.5bp in the sector after May’s preliminary PMI prints missed expectations. Belly-led gains steepened the US 5s30s by 1.8bp on the day while wider bull steepening move in gilts steepens UK 5s30s by 5bp on the day.  The US auction cycle begins at 1pm ET with $47b 2- year note sale, followed by $48b 5- and $42b 7-year notes Wednesday and Thursday.

In commodities, oil and gas stocks underperformed as crude declined amid concerns about Chinese demand, while mining shares also fall alongside metal prices. WTI is in the red but recovers off worst levels to trade back on a $109-handle. Most base metals trade poorly; LME nickel falls 4.5%, underperforming peers. Spot gold rises roughly $5 to trade above $1,858/oz.

Looking at the day ahead, we’ll get the rest of the May flash PMIs from Europe and the US, along with US new home sales for April and the Richmond Fed’s manufacturing index for May. Otherwise, central bank speakers include Fed Chair Powell, the ECB’s Villeroy and the BoE’s Tenreyro.

Market Snapshot

  • S&P 500 futures down 1.3% to 3,920.75
  • STOXX Europe 600 down 0.9% to 432.44
  • MXAP down 1.1% to 163.24
  • MXAPJ down 1.3% to 531.58
  • Nikkei down 0.9% to 26,748.14
  • Topix down 0.9% to 1,878.26
  • Hang Seng Index down 1.7% to 20,112.10
  • Shanghai Composite down 2.4% to 3,070.93
  • Sensex down 0.3% to 54,148.93
  • Australia S&P/ASX 200 down 0.3% to 7,128.83
  • Kospi down 1.6% to 2,605.87
  • Gold spot up 0.3% to $1,859.38
  • US Dollar Index down 0.11% to 101.96
  • Brent Futures down 0.2% to $113.15/bbl
  • German 10Y yield little changed at 0.99%
  • Euro up 0.2% to $1.0713

Top Overnight News from Bloomberg

  • Social media stocks are on course to shed more than $100 billion in market value after Snap Inc.’s profit warning, adding to woes for the sector which is already reeling amid stalling user growth and rate-hike fears.
  • The US must be “strategic” when it comes to a decision on whether to remove China tariffs, Trade Representative Katherine Tai said a day after President Joe Biden mentioned he would review Trump-era levies as consumer prices surge.
  • China rolled out a broad package of measures to support businesses and stimulate demand as it seeks to offset the damage from Covid lockdowns on the world’s second-largest economy.
  • China’s central bank and banking regulator urged lenders to boost loans as the economy is battered by Covid outbreaks that have threatened growth this year.
  • President Joe Biden is seeking to show US resolve against China, yet an ill-timed gaffe on Taiwan risks undermining his bid to curb Beijing’s growing influence over the region.
  • Europe’s two largest economies kept growing in May as they benefited from a sustained rebound in services that offset fallout from Russia’s invasion of Ukraine.
  • Russia’s currency extended a rally that’s taken it to the strongest level versus the dollar in four years, prompting a warning from one of President Vladimir Putin’s staunchest allies that the gains may be overdone.

A more detailed look at global markets courtesy of Newqsuawk

Asia-Pac stocks mostly declined after Snap's profit warning soured risk sentiment and weighed on US tech names. ASX 200 was rangebound but kept afloat for most of the session by resilience in tech and mining stocks, while PMIs remained in expansion territory. Nikkei 225 fell below 27,000 although losses are stemmed by anticipation of incoming relief with Finance Minister Suzuki set to present an additional budget to parliament tomorrow. Hang Seng and Shanghai Comp were pressured after further bank downgrades to Chinese economic growth forecasts, while the recent announcement of targeted support measures by China and reports of the US mulling reducing China tariffs, did little to spur risk appetite.

Top Asian News

  • Shanghai will allow supermarkets, convenience stores and drugstores to resume operations with a maximum occupancy of 50% before May 31st and 75% after June 1st, according to Global Times.
  • Hong Kong Chief Executive Carrie Lam said they are unlikely to lift the quarantine in her term, according to Bloomberg.
  • US President Biden said there is no change to the policy of strategic ambiguity regarding Taiwan, while Defense Secretary Austin earlier commented that he thinks US President Biden was clear that US policy has not changed on Taiwan, according to Reuters.
  • USTR Tai said the US is engaging with China on Phase 1 commitments of trade, while she added they must be strategic on tariffs and that President Biden's team believes trade needs new ideas, according to Reuters.
  • China's push to loosen USD dominance is said to take on new urgency amid Western sanctions on Russia and some Chinese advisers are urging the government to overhaul the exchange rate regime to turn the Yuan into an anchor currency, according to SCMP.

European bourses are subdued following the Snap-headwind, further hawkish ECB rhetoric and disappointing Flash PMIs; particularly for the UK, Euro Stoxx 50 -0.7%. US futures are similarly subdued and the Nasdaq, -1.7%, is taking the brunt of the pressure as tech names are hit across the board, ES -1.1%. Snap (SNAP) said the macroeconomic environment has deteriorated further and faster than anticipated since its last guidance issuance and it now believes it will report revenue and adjusted EBITDA below the low end of its Q2 guidance range, according to the filing cited by Reuters. Samsung (005935 KS) is to reportedly invest USD 360bln on chips and biotech over a period of five years, according to Bloomberg. Tesla (TSLA) could take until later this week to restore full production in China after quarantining thousands of workers. Uber (UBER) has initiated a broad hiring freeze across the Co. as it faces increased pressure to become profitable, according to Business Insider sources

Top European News

  • UK Chancellor Sunak ordered officials to draw up a plan for a windfall tax on electricity generators' profits, according to FT.
  • ECB's Nagel said it seems clear that the wage moderation seen for 10 years in Germany is over and they think they will see high numbers from German wage negotiations.
  • Germany's Chambers of Commerce DIHK cuts 2022 GDP growth forecast to 1.5% (vs prev. view of 3% made in Feb).

FX

  • Yen outperforms on risk off and softer yield dynamics, USD/JPY at low end of wide range stretching from just above 128.00 to just over 127.00 and multiple chart supports under the latter.
  • Franc and Euro underpinned as SNB and ECB pivot towards removal of rate accommodation, USD/CHF sub-0.9650, EUR/USD 1.0700-plus.
  • Dollar suffers as a result of the above, but DXY contains losses under 102.000 as Pound plunges following disappointing UK preliminary PMIs; Cable recoils from the cusp of 1.2600 to touch 1.2475.
  • Aussie, Loonie and Kiwi all suffer from aversion and latter also cautious ahead of RBNZ on Wednesday; AUD/USD loses grip of 0.7100 handle, NZD/USD under 0.6450 having got close to 0.6500 yesterday and USD/CAD probing 1.2800 vs virtual double bottom around 1.2765.
  • Lira loses flight to stay above 16.0000 vs Buck as Turkish President Erdogan refuses to acknowledge Greek leader and sets out plans to strengthen nation’s southern border defences.

Fixed Income

  • Gilts fly after UK PMIs miss consensus and only trim some gains in response to much better than expected CBI distributive trades
  • 10 year bond holds near the top of a 118.86-117.92 range
  • Bunds bounce from sub-153.00 lows after more hawkish guidance from ECB President Lagarde, but Italian BTPs lag under 128.00 as books build for 15 year issuance
  • US Treasuries bull-flatten ahead of 2 year note supply and Fed's Powell, T-note just shy of 120-00 within 120-02+/119-18 band
  • Italy has commenced marketing a new syndicated 15yr BTP, guidance +11bp vs outstanding March 2037 bond, according to the lead manager via Reuters; subsequently, set at +8bp.

Commodities

  • WTI and Brent are subdued amid the broader risk environment with familiar factors still in play; however, the benchmarks are off lows amid USD downside.
  • Meandering around USD 110/bbl (vs low 108.61/bbl) and USD 113/bbl (vs low USD 111.70/bbl) respectively.
  • White House is considering environmental waivers for all blends of US gasoline to lower pump prices, according to Reuters sources.
  • Spot gold is modestly firmer though it has failed to extend after briefly surpassing the 21-DMA at USD 1856/oz.

Central Banks

  • ECB's Lagarde believes the blog post on Monday was at a good time, adding we are clearly at a turning point, via Bloomberg TV; adds, we are not in a panic mode. Rates are likely to be positive at end-Q3; when out of negative rates, you can be at or slightly above zero. Does not comment on FX levels, when questioned about EUR/USD parity. Click here for more detail, analysis & reaction.
  • ECB's Villeroy says he believes the ECB will be at a neutral rate at some point next year, via Bloomberg TV; 50bps hike does not belong to the Governing Council's consensus, does not yet know the terminal rate.
  • NBH Virag says continuing to increase rates in 50bp increments is an options, increasing into double-digits is not justified.

US Event Calendar

  • 09:45: May S&P Global US Manufacturing PM, est. 57.6, prior 59.2
    • May S&P Global US Services PMI, est. 55.2, prior 55.6
    • May S&P Global US Composite PMI, est. 55.6, prior 56.0
  • 10:00: May Richmond Fed Index, est. 10, prior 14
  • 10:00: April New Home Sales MoM, est. -1.7%, prior -8.6%; New Home Sales, est. 750,000, prior 763,000

Central Banks

  • 12:20pm: Powell Makes Welcoming Remarks at an Economic Summit

DB's Jim Reid concludes the overnight wrap

These are pretty binary markets at the moment. If the US doesn’t fall into recession over the next 3-6 months then it’s easy to see markets rallying over this period. However if it does, the correction will likely have further to run and go beyond the average recession sell-off (that we were close to at the lows last week) given the rich starting valuations. For choice I don’t think the US will go into recession over this period but as you know I do think it will next year. As such a rally should be followed by bigger falls next year. Two problems with this view. Timing the recession call and timing the market’s second guessing of it. Apart from that it's all very easy!!

This week started on a completely different basis to most over the past few months. So much so that there's hope that the successive weekly losing S&P streak of seven might be ended. 4 days to go is a long time in these markets but after day one we're at +1.86% and the strongest start to a week since January. And that comes on top of its intraday recovery of more than +2% late on Friday’s session, after the index had briefly entered bear market territory, which brings the index’s gains to more than 4% since its Friday lows at around the European close. However just when you thought it was safe to emerge from behind the sofa, S&P 500 futures are -0.84% this morning with Nasdaq futures -1.42% due to Snapchat slashing profit and revenue forecasts overnight. Their shares were as much as -31% lower in after hours, taking other social media stocks with it. Asia is also weaker this morning as we'll see below.

Before we get there, yesterday's rally was built on a few bits of positive news that are worth highlighting. Investors were buoyed from the get-go by remarks from President Biden that he’d be considering whether to review Trump-era tariffs on China. It had been reported previously that such a move was under consideration, but there are also geopolitical as well as economic factors to contend with, and a Reuters report last week cited sources who said that US Trade Representative Katherine Tai favoured keeping the tariffs in place. Biden said that he’d be discussing the issue with Treasury Secretary Yellen following his return to the United States, so one to watch in the coming days with the administration under pressure to deal with inflation. This comes as the Biden administration unveiled the Indo-Pacific Economic Framework yesterday, which covers 13 countries and approximately 40% of the world’s GDP. Conspicuously, China was not one of the included parties, but US officials said there was a path for them to join. The framework reportedly does not contain any new tariff reductions, but instead seems focused on new labour, environmental, and anti-money laundering standards while seeking to build resilience. The 13 involved countries said in a joint statement, “This framework is intended to advance resilience, sustainability, inclusiveness, economic growth, fairness, and competitiveness for our economies.” It is not clear what is binding, or what Congress will think about the framework, but regardless, this is battle to halt or slow the anti-globalisation sentiment so prominent in recent years.

It was not just Biden who helped encourage the rally. We then had a further dose of optimism in the European morning after the Ifo Institute’s indicators from Germany surprised on the upside. Their business climate indicator unexpectedly rose to 93.0 in May (vs. 91.4 expected), thus marking a second successive increase from the March low after Russia’s invasion of Ukraine. This morning we’ll get the May flash PMIs for Germany and elsewhere in Europe, so let’s see if they paint a similar picture.

Ahead of that, equity indices moved higher across the world, with the S&P 500 up +1.86% as mentioned, joining other indices higher including the NASDAQ (+1.59%), the Dow Jones (+1.98%), and the small-cap Russell 2000 (+1.10%). It was a very broad-based advance, with every big sector group moving higher on the day, and banks (+5.12%) saw the largest advance in the S&P 500. Meanwhile, consumer discretionary (+0.64%) continues to lag the broader index. Over in Europe there were also some major advances, with the STOXX 600 (+1.26%), the DAX (+1.38%) and the CAC 40 (+1.17%) all rising. They have lagged the US move since Friday's Euro close mostly because they have out-performed on the downside.

Staying on Europe, we had some significant developments on the policy outlook as ECB President Lagarde published a blog post that basically endorsed near-term market pricing for future hikes. In turn, that helped the euro to strengthen against other major currencies and led to a rise in sovereign bond yields. In the post, Lagarde said that she expected net purchases under the APP “to end very early in the third quarter”, which would enable rates to begin liftoff at the July meeting in just over 8 weeks from now. Furthermore, the post said that “on the current outlook, we are likely to be in a position to exit negative interest rates by the end of the third quarter”, so implying that we’ll see more than one hike in Q3, assuming they move by 25bp increments.

Interestingly, Bloomberg subsequently reported that others at the ECB wanted to keep open the possibility of moving even faster. Indeed, it said that Lagarde’s plan had “irked colleagues” seeking to keep that option open, and was “a position that leaves some more hawkish officials uncomfortable.” So according to this, some officials want to keep the option of moving in 50bp increments like the Fed did earlier this month, although so far only Dutch central bank Governor Knot has openly referred to this as a possibility.

That move from Lagarde to endorse an exit from negative rates in Q3 sent sovereign bonds noticeably higher after the blog post was released, with 10yr bund yields giving up their initial decline to rise +7.5bps by the close, aided by the broader risk-on move. Those on 10yr OATs (+7.1bps) and BTPs (+3.3bps) also moved higher, with a rise in real yields driving the moves in all cases. Nevertheless, when it came to what the market was pricing for future rate hikes, Lagarde’s comments seemed to just solidify where they’d already reached, with the amount priced in for the ECB by year-end rising just +5.5bps to remain above 100bps.

Given the ECB’s more hawkish rhetoric of late as well as the upside Ifo reading, the Euro gained further ground against the US dollar over the last 24 hours, strengthening by +1.20% in yesterday’s session. In fact, the dollar was the second-worst performer amongst all the G10 currencies yesterday, narrowly edging out the yen, and the dollar index has now shed -2.64% since its peak less than two weeks ago. That’s in line with what our FX colleagues argued in their Blueprint at the end of last week (link here), where they see the reversal of the dollar risk premium alongside ECB tightening sending EURUSD back above 1.10 over the summer. But even though the dollar was losing ground, US Treasury yields still moved higher alongside their European counterparts, with 10yr yields up +7.0bps to 2.85%. They given back around a basis point this morning.

Over to Asia and as discussed earlier markets are weaker. The Hang Seng (-1.50%) is extending its previous session losses with stocks in mainland China also lagging. The Shanghai Composite (-1.09%) and CSI (-0.80%) are both trading lower even as the government is offering more than 140 billion yuan ($21 billion) in extra tax relief to companies and consumers as it seeks to offset the impact of Covid-induced lockdowns on the world’s second biggest economy. Among the agreed new steps, China will also reduce some passenger car purchase taxes by 60 billion yuan. Meanwhile, the Nikkei (-0.51%) and Kospi (-0.90%) are also trading in the red.

Early morning data showed that Japan’s manufacturing activity expanded at the slowest pace in three months in May after the au Jibun Bank flash manufacturing PMI slipped to +53.2 from a final reading of +53.5 in April amid supply bottlenecks with new orders growth slowing. Meanwhile, the nation’s services PMI improved to +51.7 in May from +50.7. Elsewhere, manufacturing sector activity in Australia expanded at the slowest pace in four months as the S&P Global flash manufacturing PMI fell to +55.3 in May from April’s +58.8 level while the services PMI dropped to +53.0 in May.

While markets try to judge whether or not a near-term recession is imminent and how severe it may be, another external shock to contend with is the growing Covid case count in mainland China and how stiff the lockdown measures authorities will impose to contain outbreaks. As we reported yesterday, Beijing registered record case growth over the weekend. The Chinese mainland on Monday reported 141 locally-transmitted confirmed COVID-19 cases, of which 58 were in Shanghai and 41 in Beijing. So these numbers will be closely watched over the next few days.

To the day ahead now, and we’ll get the rest of the May flash PMIs from Europe and the US, along with US new home sales for April and the Richmond Fed’s manufacturing index for May. Otherwise, central bank speakers include Fed Chair Powell, the ECB’s Villeroy and the BoE’s Tenreyro.

Tyler Durden Tue, 05/24/2022 - 08:08

Read More

Continue Reading

Uncategorized

New technology is now the beating heart of patient care

Patient care and healthcare provision have always appeared among society’s top priorities, but keeping people well came into
The post New technology…

Published

on

Patient care and healthcare provision have always appeared among society’s top priorities, but keeping people well came into sharp focus during the pandemic.

So, too, did the role of pharmaceutical companies – not least how amazing advances in medical science could help the world combat Covid, but also how the sector was remunerated for its efforts.

As we seek to move beyond the difficulties of the past few years, pharma firms now have the chance to make further advances and bring innovation to market and, in the process, gain competitive edge over their rivals.

The race is on

With an abundance of patient data to hand – GDPR compliance permitting – and cutting-edge technology to aid the development and delivery of new products, the race is on to escalate and improve patient care with solutions that can truly make a difference.

Patients aren’t blind to the tech-driven changes going on around them. We’ve been using wearable technology for decades already. Acceleration of this market really kicked in 20 years ago, when devices from Bluetooth headsets to smart watches came on-stream. Ever since, we seem to have been glued to screens to understand more about ourselves, tapping apps that promise to monitor everything from self-care to Circadian rhythms.

Wearables are becoming breakout technology in the pharma space, too. Biospace estimates the market for these types of devices that add to the patient care toolkit will grow from today’s $21.3bn to $196.5bn by 2030.

In effect, the possibilities are endless. We already have access to devices that monitor our heart rate and alert first responders if sensors detect a health crisis like a stroke or heart attack. Similar technology could be rolled out across society, accelerating critical treatment times.

Emergency response is the tip of the iceberg. All of the data produced by wearables – from blood sugar levels to monitoring changes in the menstrual cycle – can automatically be passed to frontline healthcare organisations, enabling professionals to read and appropriately respond.

Such tech is just one example of an area that is ripe with opportunity for pharma businesses. But there are lots of other exciting developments at our fingertips.

Biosimilars get the sector’s blood pumping

During the past few years, interest has been growing in biosimilars. If you’re unaware of these types of drugs, the NHS describes them as: “Biological medicines that have been shown not to have any clinical meaningful differences from the originator medicine in terms of quality, safety, and efficacy.”

Biosimilars are therefore biological medicines that are highly similar to another version already licensed for use, and they are now being recommended all the time. They are, of course, subject to the same NICE guidance as originator medicine it has already approved. NHS leaders believe biosimilars will create up to £300m of annual savings thanks to their speed of development, a timely saving in a challenging market that looks set to come under increasing financial pressure during the next few years.

Clinicians also note that the biosimilars market will rapidly develop and grow in complexity, since more pharma players will introduce their own treatments using these techniques. At the same time – with full patient/carer consent, it should be acknowledged – healthcare providers are beginning to offer patients biosimilar treatments, such that they should become widely recognised and hopefully accepted in short order.

Patients will experience biosimilars in different ways. For example, my own experience of biosimilars has been to help a global pharma company launch a biosimilar autoimmune drug. The really smart part about this development is the wider use of technology it taps into.

An app was developed so that patient symptoms could be monitored – for example, their baseline health indicators checked and logged, and dietary and exercise advice offered – and adjustments to the drug dose made accordingly by their healthcare provider.

Meanwhile, reading patient data and symptoms using this method will become commonplace. For the patient, constant improvements and updates to associated apps will present them with a slick interface to keep tabs on their own condition and ease access to support.

The wide-ranging benefits of tech-driven treatment

Of course, generations of patients have become used to traditional treatment methods. Whenever there is change it often happens slowly and people need to be persuaded about the benefits of such an evolution.

It’s useful to pause and summarise the reasons why different types of technology are now so important to developments in the pharma and healthcare sectors. Expressing its benefits can help win the hearts and minds of millions of patients the world over:

  • Constant ability to monitor symptoms – including emergency alerts
  • New interaction methods for healthcare providers and patients
  • Better control of treatment plans, including long-term care
  • Overall, a promise of quicker and more efficient service delivery

As mentioned, apps will be one of the main interfaces where this new type of professional-patient relationship takes place. According to a survey by NEJM Catalyst, a majority (60%) of clinicians and healthcare industry leaders believe effective patient engagement makes a serious impact on the quality of care, and can substantially decrease the costs in the system.

Anything that can be done to cure this problem must surely be viewed as a positive. A patient engagement app that improves the experience for physicians and patients is a valuable tool.

Digital tools augment the benefits of medical products, such as by the aforementioned remote monitoring features with the ability to collect important patient data. Overall, mobile patient engagement promises better efficiency for pharma firms’ treatments, doctors, clinics, medical associations, and the whole industry in general.

Pharma giants such as Pfizer, Merck & Co., and Novartis are actively equipping their representatives with innovative digital tools to strengthen their credibility and relevance, reconnect with target audiences, and improve the infrastructure around medical products.

The creation and provision of efficient medical apps for professionals contributes to wider efforts to overhaul treatment programmes.

Digital can be a cure-all for lack of awareness or understanding among patients about their conditions and what they can do to alleviate symptoms. It can also drive better communication between doctors and patients by removing red tape from the process, while maintaining compliance with medical regulations. And it can build efficiency into often overwrought systems, particularly the densely populated urban areas and underserved rural communities that are under the most pressure for different reasons.

Simply by providing apps that drive patient engagement and improve their experience of treatment and healthcare provision, user trust grows. Healthcare apps can be built for patients with a deep level of personalisation, with user-friendly and agile design to suit a wide range of demographic groups. And that’s really the heart of the matter.

Why connecting with the end user matters

Mass adoption of new technology-driven medicines, treatments, and healthcare services will only stand if patients – and therefore their healthcare providers – feel comfortable that this new wave will change their outcomes for the better.

Two elements are critical to society feeling comfortable: technology and communication. That means building and using platforms, from patient apps to portals for healthcare professionals that display information and advice from pharma providers.

By connecting the dots between the pharma companies using cutting-edge platforms for innovative drug delivery, their healthcare markets, and the patients who professionals exist to support we can create a virtuous circle.

Patients will play their own part in the healthcare delivery revolution and provide their data in real-time as part of a feedback loop that the pharma industry can use to refine and invent treatment.

Whether you work in pharma or frontline healthcare delivery, there is no doubt that tech innovation can – and must – be the beating heart of patient services and treatment. You only need to consider the advances it has helped other markets make. For example, observe how smarter use of customer data has shaken up the energy market, allowing consumers to take control by switching to a more suitable option in a few short clicks.

Then consider the wider advertising industry, which has evolved from mass TV marketing to one-to-one, personalised messaging, drawing on data and technology as its fuel.

It’s in this context that we should view the future of pharma and healthcare provision. Technology and the data it delivers can drive drug development, but also the use of medicine in ongoing patient care.

Health tech investment is set to swell as the private and public sectors join forces for the benefit of society at large, and patient demand for innovation in diagnosis and treatment increases. There has never been a better time for pharma leaders to consider new ways to deliver smart, efficient treatments – driven by technology that provides a platform for new medicines and user adoption.

About the author

Rachel Grigg, partnership director at LABS (part of Initials CX), has worked in digital technology for the past 25 years and has seen and been involved with the advent of digital transformation first-hand. Her roles have varied from working in large corporate companies designing technical products to being MD and COO helping small digital agencies grow and succeed.

The post New technology is now the beating heart of patient care appeared first on .

Read More

Continue Reading

International

Dinosaur teeth reveal what they didn’t eat

Scratches on dinosaur teeth could reveal what they really ate. For the first time, dental microwear texture analysis (DMTA) has been used to infer the…

Published

on

Scratches on dinosaur teeth could reveal what they really ate. For the first time, dental microwear texture analysis (DMTA) has been used to infer the feeding habits of large theropods, including Allosaurus and T. rex. By taking 3D images of individual teeth and analyzing the pattern of marks scratched into them, researchers could reason which dinosaurs may have frequently crunched on hard bone and which may have regularly eaten softer foods and prey. This technique opens up a new avenue of research for paleontology, helping us to better understand not only dinosaurs themselves but also the environment and communities in which they lived.

Credit: 2022 D.E. Winkler

Scratches on dinosaur teeth could reveal what they really ate. For the first time, dental microwear texture analysis (DMTA) has been used to infer the feeding habits of large theropods, including Allosaurus and T. rex. By taking 3D images of individual teeth and analyzing the pattern of marks scratched into them, researchers could reason which dinosaurs may have frequently crunched on hard bone and which may have regularly eaten softer foods and prey. This technique opens up a new avenue of research for paleontology, helping us to better understand not only dinosaurs themselves but also the environment and communities in which they lived.

From Fantasia to Jurassic Park, the T. rex is seen as a terrifying apex predator that would chase down its prey and crunch on it whole. But how much did this iconic dinosaur actually chow down on bones? And what about other predatory dinosaurs that existed long before it?

Researchers from the University of Tokyo, in collaboration with teams from the University of Mainz and the University of Hamburg in Germany, have used dental microwear texture analysis (DMTA), a scanning technique to examine topographical dental wear and tear in microscopic detail, on individual dinosaur teeth from more than 100 million years ago to better understand what they may have eaten. “We wanted to test if we could use DMTA to find evidence of different feeding behaviors in tyrannosaurids (from the Cretaceous period, 145 million to 66 million years ago) compared to the older Allosaurus (from the Jurassic period, 201 million to 145 million years ago), which are both types of theropods,” explained postdoctoral fellow Daniela Winkler from the Graduate School of Frontier Sciences. “From other research, we already knew that tyrannosaurids can crack and feed on bones (from studies of their feces and bite marks on bone). But allosaurs are much older and there is not so much information about them.”

DMTA has mainly been used to study mammal teeth, so this is the first time it was used to study theropods. The same research team from the University of Tokyo also recently pioneered a study on DMTA in Japanese sauropod dinosaurs, famous for their long necks and tails. A high-resolution 3D image was taken of the tooth surface at a very small scale of 100 micrometers (one-tenth of a millimeter) by 100 micrometers in size. Up to 50 sets of surface texture parameters were then used to analyze the image, for example, the roughness, depth and complexity of wear marks. If the complexity was high, i.e., there were different-sized marks which overlaid each other, this was associated with hard object feeding, such as on bone. However, if the complexity was low, i.e., the marks were more arranged, of a similar size and not overlapping, this was associated with soft object feeding, like meat.

In total, the team studied 48 teeth, 34 from theropod dinosaurs and 14 from crocodilians (modern crocodiles and alligators), which were used as a comparison. The team was able to study original fossilized teeth and take high-resolution silicon molds, thanks to loans provided by natural history museums in Canada, the U.S., Argentina and Europe. “We actually started dental microwear research of dinosaurs in 2010,” said Lecturer Mugino Kubo from the Graduate School of Frontier Sciences. “My husband, Dr. Tai Kubo, and I had started collecting dental molds of dinosaurs and their contemporaries in North and South Americas, Europe, and of course Asia. Since Daniela joined my lab, we utilized these molds to make a broader comparison among carnivorous dinosaurs.”

“It was especially challenging to carry out this research during the pandemic,” said Winkler “as we rely on being able to gather samples from international institutions. The sample size might not be so large this time, but it is a starting point.”

Winkler says what they found surprising was that they didn’t find evidence of much bone crushing behavior in either Allosaurus or tyrannosaurids, even though they know that tyrannosaurids ate bone. There may be several reasons for this unexpected outcome. It could be that although Tyrannosaurus was able to eat bone, it was less commonly done than previously thought. Also, the team had to use well-preserved teeth, so it might be that extremely damaged teeth that were excluded from this study were in such a condition because those animals fed more on bone.

Something the team did find with both the dinosaurs and crocodilians was a noticeable difference between juveniles and adults. “We studied two juvenile dinosaur specimens (one Allosaurus and one tyrannosaurid) and what we found was a very different feeding niche and behavior for both compared to the adults. We found that there was more wear to juvenile teeth, which might mean that they had to more frequently feed on carcasses because they were eating leftovers,” explained Winkler. “We were also able to detect different feeding behavior in juvenile crocodilians; however, this time it was the opposite. Juvenile crocodilians had less wear on their teeth from eating softer foods, perhaps like insects, while adults had more dental wear from eating harder foods, like larger vertebrates.”

Winkler says that the next step with dinosaurs will probably be to look in more detail at the long-necked sauropods, which the team has also been studying. But for now, she is experimenting with something much, much smaller: crickets. The insects’ mouths may be tiny and don’t have any teeth, but the researchers want to see if they can still find evidence of mouth wear using the same technique. “From what we learn using DMTA, we can possibly reconstruct extinct animals’ diets, and from this make inferences about extinct ecosystems, paleoecology and paleoclimate, and how it differs from today.” said Winkler. “But this research is also about curiosity. We want to form a clearer image of what dinosaurs were really like and how they lived all those millions of years ago.”

###

Paper Title: 

Daniela E. Winkler, Tai Kubo, Mugino O. Kubo, Thomas M. Kaiser, Thomas Tütken. First application of dental microwear texture analysis to infer theropod feeding ecology.  Palaeontology, 2022, e12632. doi:10.1111/pala.12632

Funding: 

This work was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERC CoG grant agreement no. 681450) to T.T. The Japan Society for the Promotion of Science under a Postdoctoral fellowship awarded to D.E.W. (KAKENHI Grant No. 20F20325).

Useful Links:

Graduate School of Frontier Sciences: https://www.k.u-tokyo.ac.jp/en/index.html

Mugino Kubo Lab: https://sites.google.com/edu.k.u-tokyo.ac.jp/mugino-kubo-lab/home

 

Research Contacts

JSPS Postdoctoral Fellow Daniela E Winkler, Ph.D.

Department of Natural Environmental Studies,
Graduate School of Frontier Sciences,
The University of Tokyo

5-1-5 Kashiwanoha, Kashiwa City, Chiba 277-8563

E-mail: daniela.eileen.winkler@edu.k.u-tokyo.ac.jp

Lecturer Mugino O. Kubo
Department of Natural Environmental Studies,
Graduate School of Frontier Sciences,
The University of Tokyo

5-1-5 Kashiwanoha, Kashiwa City, Chiba 277-8563

E-mail: mugino@k.u-tokyo.ac.jp

Press contact:
Mrs. Nicola Burghall
Public Relations Group, The University of Tokyo,
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan
press-releases.adm@gs.mail.u-tokyo.ac.jp

 

About the University of Tokyo
The University of Tokyo is Japan’s leading university and one of the world’s top research universities. The vast research output of some 6,000 researchers is published in the world’s top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 4,000 international students. Find out more at www.u-tokyo.ac.jp/en/ or follow us on Twitter at @UTokyo_News_en.

 

 


Read More

Continue Reading

International

Could investing in bonds yield better returns than equities in 2023?

It’s not news that 2022 has been a tough one for stock markets. There have been sectors, like energy and utilities, that…
The post Could investing…

Published

on

It’s not news that 2022 has been a tough one for stock markets. There have been sectors, like energy and utilities, that have bucked the negative trend but the big picture has been bleak. The UK’s large cap FTSE 100 index has faired better than most and is more or less flat for the year thanks to its heavy weighting towards energy, industrial commodities, and finance.

Source: CSIMarket

But it’s been a volatile ride and the end of the year could still drag London’s benchmark index into the red.

ftse100index

Over in the USA, the major indices have suffered significant losses. The growth companies, especially in the tech sector, that saw Wall Street enjoy over a decade of strong growth with only the occasional short-lived correction have been among those hit hardest by inflation hitting decades-long highs and interest rates rising.

That’s seen the tech-heavy Nasdaq Composite register an over 30% loss for the year-to-date and the broader based S&P 500 is down a little under 18% over 2022.

nasdaq composite

However, while the hangover from the Covid-19 pandemic and Russia’s invasion of Ukraine were unpredictable events that have undoubtedly deepened stock market losses, a turn of the market cycle is not a surprise. The bull market that preceded the 2022 bear market was the longest in history, supported by unprecedented levels of quantitative easing and record-low interest rates in major developed economies.

If anything, the surprise was that the bull market for equities persisted for as long as it did and pushed valuations so high. More bearish analysts had been warning of a reversal for years before it actually transpired.

What has been far more surprising, almost unprecedented, is that bond markets have failed to live up to their traditional portfolio role of providing insurance against an equities bear market. When equities, especially growth stocks, enter bear territory, bonds usually go in the opposite direction, rising with interest rates and an influx of capital seeking a safe haven.

Traditionally, a portfolio with a 60% allocation to equities and 40% allocation to bonds should come into its own during periods like this year. The bond allocation would be expected to cushion the blow of an equities bear market, paying its way for lower returns than equities during the good times.

But in the third quarter of this year, a traditionally conservative portfolio with a 40% allocation to equities would have actually underperformed one 100% allocated to equities. Inflation remaining stubbornly high this year despite the Fed and other central banks including the Bank of England has upended the conventional investing wisdom that equities and bonds do not both move in the same direction – the foundational principle of traditional diversification strategies.

But will that change in 2023? Could bonds outperform equities next year in a way that means investors should consider increasing their portfolio weighting towards fixed-income investments?

Why have bonds not lived up to their billing in 2022?

Nothing has worked well for diversified investors this year, not equities, not bonds and not the traditional 60/40 portfolio split between the two asset classes. But will this year prove a blip or has the relationship bet equities and bonds changed fundamentally?

Analysts including Morningstar’s Lauren Solberg believe the performance of the bond market next year will be most influenced by inflation. If inflation remains high, bonds could continue to struggle alongside equities. However, if major central banks including the Fed manage to wrestle inflation back down towards target levels, especially if that is accompanied by a recession, bonds would be expected to revert to their traditional anti-correlation with equities.

This year, one they would have been expected to benefit from a flight from equities and rising interest rates, has been the worst for bonds in modern history. It’s also been the only time in history that stocks and bonds have both recorded losses for three consecutive quarters.

chart2

Source: Morningstar

Sky-high inflation, which is bad for both equities and bonds, has negated the usually positive impact on bonds of a bear market for equities and rising interest rates.

Will bonds return to form in 2023?

There is differing opinion among analysts and market observers about what 2023 might hold in store for bond markets. The more common expectation is that bonds will do a much better job at insulating portfolios than this year with yields now much higher than they were in late 2021.

However, others believe that a secular change in the correlation relationship between equities and bonds is now underway. That is based on the expectation that inflation, even if it falls meaningfully in 2023, could remain at higher levels and be more prone to volatility than it has been over the past couple of decades.

Recent research published by Truist Wealth shows that U.S. government-backed debt has delivered average annual returns of 6.6% over the past four recessions, beating both high-yield ‘junk’ and investment-grade corporate bonds. That would indicate 2023 could be a very good year for bond investors with the right exposure – a focus on government rather than private sector debt. However, we’ve already seen a significant divergence from historical patterns this year.

Marta Norton, chief investment officer for the Americas at Morningstar Investment Management, believes 2023 could be hold opportunities for fixed income, across government-backed and corporate bonds:

“When you look over the past 10 years, it’s really only been an equity story: It’s been such a good market to take on equity risk, a tremendously good time to be an equity investor. But today, it’s harder to know where to invest the marginal dollar. Fixed income is looking more appealing than it has in some time. You don’t have to take enormous risk to earn some return, and that’s a mindset shift to the environment we had before.”

While she acknowledges that U.S. equities now look a lot more attractively priced than they did a year ago, she cautions against investors rushing back to the market and thinks the bear cycle could last longer than many expect. She says the “buy the dip”mentality that has worked so well over the past decade could mean investors risk suffering meaningful losses by moving into a losing market.

She doesn’t advise not investing in equities but that investors should instead drip feed any investment instead of trying to time a bottom.

She is more confident in the opportunities around fixed income investments, especially higher-quality, shorter-dated fixed income, which she says comes with the added benefit of lower risk, especially if a deeper recession materialises.

Christian Mueller-Glissmann, head of asset allocation research within portfolio strategy at Goldman Sachs agrees. He notes the gap in yields between stock and bonds has narrowed substantially since the COVID-19 crisis and is now relatively low. The same is true for riskier credit, which yields relatively little compared with practically risk-free Treasuries and means investors are getting little premium for the risk of owning equities or high-yield credit in comparison to lower-risk bonds. As a result, equities and high-yield debt are particularly exposed to an economic slowdown or recession:

“That just makes equities and riskier debt very vulnerable for disappointments on growth next year”.

Lisa Shalett, chief investment officer of Wealth Management at Morgan Stanley is also championing bonds for 2023. She concludes:

“We continue to believe it is premature to call an end to the bear market for U.S. stocks. Investors may have moved on from inflation concerns, but they cannot ignore the economic picture. For now, investors should consider reducing U.S. large-cap index exposure. Instead, look to Treasuries, munis and investment-grade corporate credit. Stay patient and collect coupon income.”

What about UK Gilts vs London-listed equities?

Should investors mainly exposed to London-listed rather than Wall Street-based equities be thinking along similar lines? The FTSE 100 has remained largely flat in 2022, finally benefitting from its lack of growth stocks and heavy weighting to more traditional sectors like energy, commodities and finance.

London-listed equities were considered cheap before 2022, which is another reason valuations have not fallen in the same way as they have in the USA. On the other hand, they are also less likely to see as much upside if a recession is avoided next year and economic sentiment improves.

The FTSE 100 has also been boosted considerably by the soaring valuation of big energy companies like BP and Shell and utilities such as Centrica, which has compensated for companies in other sectors, such as consumer cyclicles, losing value. Energy prices easing off next year, which is by no means guaranteed depending on how geopolitical factors play out, would be negative for the benchmark index.

The UK’s outlook for both equities and government debt is not particularly positive. RBC Wealth Management summarises:

“A crippling cost of living, austerity measures, and the Bank of England tightening monetary policy will all conspire to create a prolonged recession in the UK, in our view. We advocate an underweight position in UK equities, although we are mindful that depressed valuations may produce interesting dividend income opportunities. We have a negative outlook on UK sovereign debt, as increased government debt issuance and the Bank of England proceeding to sell its Gilts portfolio will likely create a Gilt supply glut.”

While it may not appeal to patriotic sentiment, investors looking for the best risk-to-reward ratio in 2023 might be better served to invest in U.S. Treasuries than UK Gilts if a fixed income approach is favoured.

The post Could investing in bonds yield better returns than equities in 2023? first appeared on Trading and Investment News.

Read More

Continue Reading

Trending